During the 61 stAmerican Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub was pleased to speak to Ann Lacasce, Dana-Farber Cancer Institute, Boston, US. We asked: How can we tackle immune evasion in Hodgkin lymphoma?
Ann Lacasce discusses new immunotherapies in lymphoma. She talks about the results of clinical trials that assess the efficacy of checkpoint inhibitors and CAR T therapy. She explains that she anticipates the results will potentially be tolerable and durable